Cases of bilateral breast metastasis of serous ovarian carcinoma in the literature
| Author (year) | Age | Stage | Presentation | Lymphadenopathy | Histology | Treatment | Serum | Immuno-histochemistry | Outcome (interval*) |
| Krishnan (1980)1 | 60 | N/A | Edema, Erythema, Induration, Tenderness | None | Papillary serous, psammoma bodies | Chemotherapy, radiation | N/A | N/A | Death (6 months) |
| Hughes (1983)2 | 48 | N/A | Mass | Axillary | Papillary adenocarcinoma | Mastectomy | N/A | N/A | Death (5 months) |
| Wadhwa (1999)3 | 45 | IV | Induration, Peau d’orange | Axillary, supraclavicular | Papillary serous, focal calcifications, psammoma bodies | Chemotherapy, mastectomy, radiation | CA-125 | N/A | Progression (25 months) |
| Ozgüroğlu (1999)4 | 55 | IIIc | Edema, Erythema, Induration | Supraclavicular | Papillary adenocarcinoma | N/A | CA-125 | N/A | Death (3 months) |
| Özsaran (2000)5 | 41 | N/A | Edema, Mass, Nipple retraction, Peau d’orange | Axillary | Papillary serous, microcalcifications | Chemotherapy | CA-125 | p53 (+) | Death (N/A) |
| Oksüzoğlu (2001)6 | N/A | IIIc | N/A | Axillary | Papillary cyst-adenocarcinoma | Chemotherapy | CA-125 | N/A | Partial response (18 months) |
| Kayikçioğlu (2001)7 | 33 | IIIc | Erythema, Induration, Tenderness | Axillary | Papillary serous | Chemotherapy, hormone therapy | CA-125 | OC125 (+)GCDFP (−)ER (−) | Death (18 months) |
| Gökaslan (2005)8 | 68 | N/A | Mass | Axillary | Papillary serous cystadenocarcinoma | Chemotherapy | N/A | CA-125 (+), CA15-3 (+) | N/A (N/A) |
| Fulciniti (2008)9 | 49 | III | Mass | None | Serous carcinoma, microcalcifications, psammoma bodies | Chemotherapy | N/A | CA-125 (+)WT-1 (+) | N/A (N/A) |
| Khalifeh (2009)10 | 56 | IV | Erythema | Axillary | Serous carcinoma, calcifications, psammoma bodies | Chemotherapy, hormone therapy, mastectomy, radiation | CA-125, CA27.29 | ER (+),PR (−),WT-1 (+), GCDFP (−) | Good response (16 months) |
*Interval: since breast involvement.
CA-125, cancer antigen 125; CA 15-3, cancer antigen 15-3; ER, estrogen receptor; GCDFP, gross cystic disease fluid protein; OC-125, monoclonal antibody for CA-125 antigen; WT-1, Wilms’ tumour-1 antigen.